Carlos Mateos-Cuesta

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.

Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.

Journal: Science translational medicine

Published: June 28, 2023

Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.

Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.

Journal: Hematological oncology

Published: April 18, 2023

Dasatinib-induced spleen contraction leads to transient lymphocytosis.

Dasatinib-induced spleen contraction leads to transient lymphocytosis.

Journal: Blood advances

Published: November 02, 2022

Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.

Ibrutinib Does Not Impact CCR7-Mediated Homeostatic Migration in T-Cells from Chronic Lymphocytic Leukemia Patients.

Journal: Cancers

Published: May 19, 2022

CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.

CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.

Journal: Frontiers in oncology

Published: July 05, 2021

Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.

Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.

Journal: mAbs

Published: May 04, 2021

Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.

Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.

Journal: Cancer immunology, immunotherapy : CII

Published: February 02, 2021

Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.

Journal: Frontiers in immunology

Published: February 01, 2021

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.

CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.

Journal: Biomarker research

Published: September 05, 2020

Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease.

Evaluation of therapeutic targeting of CCR7 in acute graft-versus-host disease.

Journal: Bone marrow transplantation

Published: July 18, 2019

Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.

Immediate Effects of Dasatinib on the Migration and Redistribution of Naïve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients.

Journal: Frontiers in pharmacology

Published: April 15, 2019

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Journal: Frontiers in immunology

Published: September 23, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026